Somewhat Positive News Coverage Somewhat Unlikely to Impact Catalyst Biosciences (CBIO) Stock Price
Headlines about Catalyst Biosciences (NASDAQ:CBIO) have trended somewhat positive on Thursday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalyst Biosciences earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.9726724094751 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors – GlobeNewswire (press release) (globenewswire.com)
- Catalyst Biosciences, Inc. (CBIO) – Technical Interpretation with Stock Charts – Wall Street Morning (wallstreetmorning.com)
- 30 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga (benzinga.com)
- Catalyst Biosciences, Inc. (NASDAQ:CBIO) Moving Today – Up $0.02 – First News 24 (firstnewspaper24.com)
Shares of Catalyst Biosciences (CBIO) traded down 1.69% during trading on Thursday, hitting $4.64. 129,511 shares of the company’s stock were exchanged. The stock’s market cap is $20.00 million. Catalyst Biosciences has a 1-year low of $3.11 and a 1-year high of $21.30. The stock’s 50-day moving average price is $4.68 and its 200-day moving average price is $4.38.
Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.46) by ($1.07). Catalyst Biosciences had a negative net margin of 3,127.92% and a negative return on equity of 92.61%. The company had revenue of $0.11 million during the quarter. On average, equities analysts expect that Catalyst Biosciences will post ($7.91) earnings per share for the current fiscal year.
WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/26/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-catalyst-biosciences-cbio-stock-price.html.
About Catalyst Biosciences
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Stock Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related stocks with our FREE daily email newsletter.